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1. Introduction 
Hepatic encephalopathy (HE) is one of the major complications of liver cirrhosis. It has a 
considerable socioeconomic impact as it reduces the individual’s quality of life and needs 
repeated admission in hospital for its treatment. HE is a complex neuropsychiatric 
syndrome, which may complicate acute or chronic liver failure and defined as a disturbance 
in central nervous system function because of hepatic insufficiency and after exclusion of 
other brain disease. Traditionally, HE is graded according to the West Haven criteria, which 
define HE grades I–IV based on the presence of specific clinical signs and symptoms and 
their severity (1,2). The Working Party proposed a nomenclature of HE and classified into 
three types : type A, associated with acute liver failure; type B, associated with the existence 
of porto-systemic communications without intrinsic liver disease; and type C, associated 
with cirrhosis, which, depending on the manner of presentation, is classified into episodic 
HE (related to precipitating factors) or spontaneous (persistent HE)(1). However, patients 
with cirrhosis present with a continuous severity spectrum of neuropsychological 
symptoms ranging from entire normality (HE 0) up to obvious deficits (3). Even in minimal 
HE (MHE) without obvious clinical symptoms, neuropsychological and neurophysiological 
testing uncovers deficits which impact on the quality of life and the fitness to drive a motor 
vehicle (4-7).In this article we will focus mainly on treatment of HE related to cirrhosis 
(type-C) using disaccharides. 
2. Pathophysiology of HE and role of ammonia 
The pathogenesis of HE in cirrhosis is complex and has multiple components, including 
ammonia, inflammatory cytokines, benzodiazepine-like compounds, and manganese, that 
cause functional impairment of neuronal cells. Numerous factors have been shown to 
precipitate HE including infections, sedatives, gastrointestinal bleeding, dietary protein 
excess, diuretics, and electrolyte imbalance (8) 
There is consensus that ammonia is a key toxin in HE, which may sensitize the brain to the 
different precipitating factors(9,10). Ammonia is created primarily from nitrogenous 
products in the diet, bacterial metabolism of urea and proteins in the colon, and from 
deamination of glutamine in the small intestine by the enzyme glutaminase(11,12). Due to 
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hepatocellular dysfunction and portosystemic collaterals in cirrhosis, the ammonia 
concentration rises in the bloodstream and crosses the blood-brain barrier. Exposure to 
ammonia results in structural alterations in neurons manifested primarily as astrocyte 
swelling resembling Alzheimer type II astrocytosis (13,14).In chronic liver disease, urea 
synthesis is impaired and the brain acts as an alternative major ammonia detoxification 
pathway. Astrocytes have the ability to eliminate ammonia by the synthesis of glutamine 
through amidation of glutamate by the enzyme glutamine synthetase (15-18). Glutamine 
enters the mitochondria (Trojan horse hypothesis) and is subsequently cleaved by 
glutaminase to ammonia and glutamate, thereby increasing intracellular ammonia levels. 
This causes a feed-forward loop as elevation in mitochondrial ammonia causes production 
of reactive nitrogen and oxygen species (RNOS) leading to further edema(19-22).Studies 
have also examined the role of ammonia-induced potentiation of aquaporin-4, a water 
channel expressed copiously in astrocytes(23). Astrocyte edema also causes depletion of 
taurine, a molecule that serves as an antioxidant and helps to buffer ammonia-induced 
toxicity(24).Increased ammonia levels cause abnormal cerebral blood flow and glucose 
metabolism. Single photon emission computed tomographic (SPECT) studies have 
demonstrated altered cerebral perfusion with hyperammonemia resulting in a redistribution 
of blood flow from the cortex to the subcortical regions, which was associated with impaired 
performance on neuropsychiatric testing(25). Further support for the ammonia–glutamine– 
brain water hypothesis has been provided by inducing hyperammonemia in patients with 
cirrhosis through the oral administration of an amino acid solution. An increase in brain 
glutamine, reduction in magnetization transfer ratio, and significant deterioration in 
neuropsychological function was suggestive of an increase in brain water (26). 
3. Treatment of HE 
The most important aspect of HE management is prompt recognition and treatment of 
precipitating factors. Fessel and colleagues demonstrated that HE is caused by reversible 
factors in over 80% of patients(27). These common reversible factors include constipation, 
infection, hypokalemia, gastrointestinal bleeding, increased protein intake, sedatives, and 
tranquilizers. Thus, identifying and correcting the reversible precipitating factors can be 
beneficial in treating most episodes of HE. Administration of various ammonia-lowering 
therapies such as nonabsorbable disaccharides and selected antimicrobial agents and other 
less utilized alternative and investigational treatment options include administration of 
benzodiazepine receptor antagonists, branched-chain amino acids (BCAAs) and ornithine 
aspartate. If infection is suspected or the patient has clinical evidence of ascites, a 
paracentesis should be performed with analysis of cell count, gram stain, and culture to 
evaluate for spontaneous bacterial peritonitis. Additional investigations for infection should 
be performed with blood cultures, urinalysis, or chest radiographs. Broadspectrum 
antibiotics should be initiated after obtaining cultures if infection is suspected, especially in 
patients with stage III or IV HE. Hypokalemia can be corrected with oral or intravenous 
potassium. Severe hyponatremia, particularly serum sodium less than 120 mEq/L, should 
be addressed with appropriate free-water restriction(28). Vasopressin receptor antagonists 
may be considered for symptomatic patients with severe hyponatremia. HE precipitated by 
dietary protein intake or use of sedatives often resolves gradually with supportive care 
(29,30). 
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4. Non-absorbable disaccharides and mechanism of action 
Non-absorbable disaccharides are recommended as first-line pharmacotherapy in current 
guidelines(2,28). 
Current therapies for HE are based on ammonia lowering, with the hypothesis that the 
colon is the primary organ that generates ammonia (2,28). Lactulose is the most 
commonly utilized non-absorbable disaccharide for HE. Lactulose, a synthetic 
disaccharide, is comprised of the monosaccharides lactose and galactose, and is available 
as a syrup. Doses are generally titrated to achieve two to four semi-soft stools daily, with 
typical doses of 20 g/30mL orally three to four times per day. A second non-absorbable 
disaccharide, lactitol, has also been used in the treatment of HE, but it is not currently 
commercially available in some countires like US(31,32). Lactitol (p-galactosido-sorbitol) 
is a disaccharide analog of lactulose which is neither absorbed nor broken down in the 
small intestine , but is extensively metabolized by colonic bacteria. It is available in a 
highly soluble crystalline powder form and is reported to be less sweet in taste than 
lactulose. Clinical trials have reported lactitol dosages of 10-12 g every 6 hours, titrated to 
two bowel movements daily to be effective in treatment of HE (31,33). Disaccharides (both 
lactulose and lactitol) remain undigested until they reach the colon, where they get 
metabolized by the bacteria in the colon to acetic and lactic acid. This acidification of 
colonic lumen inhibits bacterial ammonia production and trap ammonia as non-diffusable 
ammonium in the intestinal lumen.Due to their cathartic effect it facilitates a 4-fold 
increase in faecal nitrogen excretion. Both effects result in reduced levels of ammonia in 
the colon and portal blood. (Figure-1)(34-36). 
Non –absorbable disaccharides
(Lactulose and lactitol)
Increased frequency of stools
Decrease in ammonia absorption
Lactic acid and acetic acid in large bowel
Decrease in pH
Increase in NH4
+
Increase in non ammoniagenic lactobacilli
 
Fig. 1. Mechanism of actions of disaccharides. 
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5. Clinical efficacy of non-absorbable disaccharides 
5.1 Lactulose or lactitol versus placebo or no intervention 
5.1.1 Overt hepatic encephalopathy 
The non-absorbable disaccharides have been a mainstay of therapy for HE for decades, and 
have been extensively studied in several small clinical trials since the late 1960s for this 
indication. In most of these trials patients had cirrhosis with acute, chronic, acute or chronic 
or minimal hepatic encephalopathy (37-44). Oral lactulose was used in majority of these 
studies though some had used lactitol and lactulose enemas also (40). In most of the studies 
the daily mean doses of lactulose ranged from 30 g to 80 g (median 50 g) to obtain two to 
three semisoft stools per day. The median duration of treatment was 15 days (range 5 to 360 
days). None of the trials followed up patients after the end of treatment. Uribe M et al (40) 
performed a double-blind, controlled trial to study the efficacy of acidifying enemas of 
lactitol and lactose versus nonacidifying tap-water enemas in 45 episodes of acute portal-
systemic encephalopathy. A favorable response to treatment was obtained in 19 (86%) of the 
patients receiving lactitol enemas and in 14 (78%) of those receiving lactose enemas. They 
concluded that acidifying agents like lactose and lactitol are effective and superior to tap-
water enemas for the treatment of acute nitrogenous portal-systemic encephalopathy. Study 
by Mas et al(45) in 53 patients with acute hepatic encephalopathy which were treated with 
lactitol 60g/day for 5-10 days concluded lactitol to be effective in 81% of patients. A recent 
meta-analysis evaluated 22 clinical trials in order to better assess the utilization of non-
absorbable disaccharides in the management of HE when compared with placebo, no 
intervention or antimicrobials. Compared with placebo or no intervention, lactulose and 
lactitol seemed to reduce the risk of no improvement of hepatic encephalopathy (relative 
risk 0.62, 95% confidence interval 0.46 to 0.84).However high quality trials found no 
significant effect of lactulose or lactitol on the risk of no improvement (0.92, 0.42 to 2.04), 
whereas low quality trials found a significant beneficial effect of lactulose or lactitol (0.57, 
0.40 to 0.83)(46,47). At the present time, however, there is a lack of sufficient evidence to 
thoroughly refute the use of non-absorbable disaccharides for the treatment of HE. Sharma 
et al(48) had shown that high baseline model for end stage liver disease(MELD), high total 
leukocyte count, low serum sodium, low mean arterial pressure, and presence of 
hepatocellular carcinoma were predictors of nonresponse to lactulose. 
6. Disaccharides in treatment of minimal hepatic encephalopathy 
Trials in patients with minimal hepatic encephalopathy (MHE) found that lactulose or lactitol 
significantly reduced the risk of no improvement assessed by various psychometric tests (0.61, 
0.47 to 0.79). Compared with placebo or no intervention, lactulose and lactitol had no 
significant effect on mortality but tended to lower blood ammonia. A summary analysis of 
some clinical trials of non-absorbable disaccharides versus placebo/ no treatment is shown in 
table-1.In a recent study Prasad et al(44) found that treatment with lactulose improved both 
cognitive function and health-related quality of life, as measured by the Sickness Impact 
Profile(SIP), when compared against a ‘no treatment’ patient group. The mean total SIP score 
improved among patients in the treated group (baseline, 10.39 [95% CI 9.36-11.43]; after 3 
months, 3.77 [95% CI 2.52-5.02]) compared with patients in the untreated group (baseline, 
10.36 [95% CI 8.98-11.73]; after 3 months, 10.39 [95% CI 8.36-12.42]);p=0.002. Improvement in 
health related quality of life (HRQOL) was related to the improvement in psychometry. Study 
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by Sharma et al had shown that on univariate and multivariate analysis, serum sodium and 
venous ammonia were the only two parameters associated with nonresponse to lactulose(49). 
Reported adverse events were not serious, and all originated from the gastrointestinal tract 
(diarrhoea, flatulence, abdominal pain, or nausea)(46). 
Trial Study 
design 
Patients No treatment Assessment Efficacy 
Simmons et 
al (1970)(37) 
Parallel AHE+CHE 26 Lactulose 
/glucose 
Clinical grading, 
ammonia, stool 
production 
Lactulose= 
glucose 
Rodgers et al 
(1973)(38) 
Crossever CHE 6 Lactulose 
/sorbitol 
Clinical grading, 
EEG, Ammonia 
Lactuose= 
sorbitol 
Corazza et 
al(1982)(39) 
Parallel CHE 32 Lactulose 
/placebo 
Encephalopathy 
intensity score, 
ammonia 
Lactulose  
better than 
placebo 
Uribe et al 
(1987)(40) 
Parallel AHE 15 Lactulose  
enema 
Mortality, clinical 
grading 
Lactulose> 
placebo 
Horsmans et 
al (1997)(41) 
Parallel MHE 14 Lactulose 
/placebo 
Psychometric tests, 
ammonia levels 
Lactulose > 
placebo 
Wantabe et 
al (1997)(42) 
Parallel MHE 36 Lactulose 
/ no treatment 
Three psychometric 
tests, ammonia 
Lactulose > 
placebo 
Dhiman et al 
(2000)(43) 
Parallel MHE 26 Lactulose 
/ no treatment 
psychometric tests Lactulose > 
placebo 
Prasad et al 
(2007)(44) 
Parallel MHE 61 Lactulose 
/ no treatment 
psychometric tests 
and HRQOL 
Lactulose > 
placebo 
AHE: acute hepatic encephalopathy CHE: Chronic hepatic encephalopathy 
MHE: Minimal hepatic encephalopathy EEG: Electroencephalography 
Table 1. Comparison of non absorbable disaccharides and placebo or no treatment for 
hepatic encephalopathy. 
7. Lactulose versus lactitol for the treatment of hepatic encephalopathy 
Lactulose and lactitol both have been used for the treatment of HE and lactulose has been 
compared with lactitol in various studies (32,33,50-57)(Table-2).Morgan et al(32) enrolled 
twenty-five cirrhotic patients experiencing 28 episodes of acute hepatic encephalopathy 
which were randomized blindly to treatment with either lactitol (n = 15) or lactulose  
(n = 13). At the end of the trial, 67% of the patients in the lactitol group and 69% of the 
lactulose group were clinically normal. Metaanalysis by Blanc et al(56) studied the efficiency 
and tolerance of both compounds(lactulose and lactitol) by using a meta-analysis on the 
basis of published controlled trials. Analyzed parameters were the portosystemic 
encephalopathy index of Conn after treatment, the percentage of improved patients and the 
percentage of patients who had ill effects related to the treatment (flatulence, diarrhea). 
Bibliographical screening revealed five studies comparing the effects of lactitol and lactulose 
in chronic hepatic encephalopathy. Four crossover studies were done that included 48 
patients and one parallel study that included 29 patients. The duration of the treatment 
ranged from 3 to 6 months. All studies found a similar efficiency with both drugs. However, 
they exhibited some discrepancies in the relative frequency of adverse reactions (flatulence). 
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Meta-analysis showed no statistical differences in the portosystemic encephalopathy index 
after lactitol or lactulose treatment. The percentage of improved patients after lactitol or 
lactulose was similar. In contrast, the analysis revealed a higher frequency (p less than 0.01) 
of flatulence in patients treated with lactulose compared with those treated with lactitol(56). 
In conclusion, this meta-analysis shows no statistical difference between therapeutic effects 
of lactitol and lactulose, but it does show a higher frequency of flatulence with lactulose. 
However another metaanalysis by Camma et al (57) showed that lactitol was as effective as 
other disaccharides in the treatment of encephalopathy: pooled odds ratio was 0.83, 95% 
confidence interval was 0.38-1.82. Patients experienced fewer side effects during treatment 
with lactitol, but the pooled odds ratio was not statistically significant. In all studies lactitol 
was considered more palatable (50,55). Clinical effectiveness of lactitol, in long-term 
treatment of chronic encephalopathy, is similar to those of lactulose. It seems that lactitol has 
lower side effects than lactulose. 
 
Trial Study design Patients No 
Treatment 
duration 
Assessment Efficacy 
Lanthier et 
al (1985)(50) 
Crossover CHE 5 6 months Clinical examination, 
psychometric tests, 
ammonia levels, EEG, 
cerebral blood flow 
Lactulose 
=lactitol 
Morgan and 
Hawley et 
al(1987)(32) 
Parallel, 
double blind 
AHE 25 5 days Psychometric tests, 
EEG, PSE index 
Lactulose 
=lactitol 
Heredia et 
al(1987)(51) 
Parallel AHE 40 5 days Mortality, clinical 
grading, PSE grade, 
adverse events 
Lactulose 
=lactitol 
Heredia et 
al(1988)(34) 
Randomized, 
crossover 
CHE 25 6months Psychometric tests, 
ammonia levels, EEG, 
PSE index 
Lactulose 
=lactitol 
Morgan et 
al(1989)(52) 
Double-blind, 
randomized, 
Crossover 
MHE 9 3 months Psychometric tests, 
ammonia levels, EE 
Lactulose 
=lactitol 
Riggio et al 
1989(53) 
Parallel CHE + 
MHE 
31 6 months PSE Index, new 
episodes of HE, 
adverse events 
Lactulose 
=lactitol 
Grandi 
1991(54) 
Cross-over CHE 40 - PSE Index, adverse 
events 
Lactulose 
=lactitol 
Pai et al 
1995(55) 
Parallel AHE 45 5 days PSE Index, adverse 
events 
Lactitol>la
ctulose 
Blanc P et al 
1992(56) 
Metaanalysis CHE 77 3-6months PSE Index Lactulose 
=lactitol 
Cammà C et 
al 1993(57) 
Metaanalysis CHE - - PSE Index Lactulose 
=lactitol 
AHE: acute hepatic encephalopathy CHE: Chronic hepatic encephalopathy 
MHE: Minimal hepatic encephalopathy PSE Index: Portosystemic encephalopathy index 
Table 2. Comparison of lactulose and lactitol for hepatic encephalopathy. 
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8. Comparison of lactulose and antimicrobial agents for hepatic 
encephalopathy 
Certain oral antibiotics can reduce urease-producing bacteria in the intestines, resulting in a 
decrease of ammonia production and absorption through the gastrointestinal tract. 
Antibiotics are used generally in patients who do not tolerate nonabsorbable disaccharides 
or in patients who are symptomatic on nonabsorbable disaccharides and require a second 
agent. Antibiotics with activity against urease-producing bacteria (e.g. neomycin, 
metronidazole) are effective in reducing intestinal ammonia production. However, the 
safety and efficacy of these antibiotics in treatment of HE have not been adequately 
demonstrated. Neomycin and other antimicrobials are utilized as a treatment modality in 
HE due to their ability to inhibit ammonia production by intestinal bacteria(58). Conn et 
al(58) conducted a randomized double blind clinical comparison of neomycin and 
lactulose in 33 cirrhotic patients with chronic portal-systemic encephalopathy. Serial 
assessments were made in all patients regarding mental status, asterixis, trailmaking test 
(TMT), electroencephalograms (EEG) and arterial ammonia levels. Both neomycin-sorbitol 
and lactulose were effective in the majority of patients (83 and 90%, respectively. 
Atterbury et al (59) evaluated in double-blind, randomized study the efficacy of lactulose 
and compared with neomycin-sorbitol in 45 episodes of acute nitrogenous portal-systemic 
encephalopathy (PSE) induced by dietary protein, azotemia, or gastrointestinal 
hemorrhage. All patients had underlying cirrhosis, and at the time of randomization had 
encephalopathy of at least grade 2 severity and arterial ammonia concentrations greater 
than 150 microgram/100 ml. Two thirds of the patients in each group returned to normal 
mental status and more than 80% in each group showed at least one grade improvement in 
mental state. In addition, there was equivalent improvement in asterixis, in the performance 
of the Number Connection Test, in the electroencephalographic pattern, and in arterial 
ammonia concentration. The principal difference between the two groups was a greater 
reduction in stool pH after lactulose therapy than after neomycin-sorbitol therapy. Other 
antimicrobials, including metronidazole and vancomycin, have been studied to a more 
limited extent than neomycin(59-61)(Table-3). Orlandi et al (60) conducted a randomized  
Trial Study design 
No of 
patients 
Duration of 
treatment 
Assessment Efficacy 
Conn et 
al(1977)(58) 
Neomycin vs 
lactulose 
(double-blind, 
randomized, 
crossover) 
29 10 days 
each 
arm before 
crossover 
Mental status, 
asterixis 
score, EEG, ammonia 
levels, PSE index 
Neomycin = 
lactulose 
Atterbury et 
al(1978)(59) 
Parallel 47 7 days Mental status, 
asterixis 
score, EEG, ammonia 
levels, PSE index 
Neomycin = 
lactulose 
Orlandi et 
al(1981)(60) 
Single blind 173 14 days Mental status, 
asterixis 
score, EEG, ammonia 
levels, HE change 
Neomycin = 
lactulose 
EEG: Electroencephalography 
Table 3. Comparison of lactulose and neomycin for hepatic encephalopathy. 
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Trial Study design 
No of 
patients 
Duration of 
treatment 
Assessment Efficacy 
Festi et 
al(1993)(64) 
Lactulose 
(open-label) 
21 21 
Neurological 
signs of HE, 
asterixis score, 
HRNB, EEG, 
ammonia levels 
Rifaximin 
=lactulose 
Bucci and 
Palmieri 
(1993)(68) 
Lactulose 
(double-blind, 
double-
dummy) 
58 15 
Neurological 
status, asterixis 
score, HRNB, 
cancellation tasks, 
EEG, ammonia 
levels 
Rifaximin 
>lactulose 
Massa 
et al(1993)(70) 
Lactulose 
(double-blind, 
double-
dummy) 
40 15 
HE index severity, 
mental status, 
cancellation tasks, 
HRNB, EEG 
Rifaximin 
>lactulose 
Fera et 
al(1993)(72) 
Lactulose 
(double-blind, 
double-
dummy) 
40 
First 2 weeks 
of each month 
for 3 months 
Mental status, 
asterixis score, 
cancellation 
tasks, HRNB, 
EEG, ammonia 
levels, PSE 
index 
Rifaximin 
>lactulose 
Mas et 
al(2003)(71) 
Lactitol 
(double-blind, 
double-
dummy) 
103 5–10 days 
Mental status, 
asterixis score, 
EEG, 
ammonia levels, 
PSE index, 
psychometric 
tests 
Rifaximin 
= lactitol 
Leevy et 
al(2007)(73) 
Lactulose 
(crossover) 
145 
>6 months 
lactulose 
>6 months 
rifaximin 
HE grade, 
asterixis score 
Rifaximin 
>lactulose 
Paik et 
al(2005)(74) 
Lactulose 
(open-label) 
54 7 days 
Ammonia levels, 
flapping tremor, 
mental 
status, HE index, 
psychometric tests 
Rifaximin 
= lactitol 
Jiang Q et 
al(2008)(76) 
meta-analysis 264 - - 
Rifaximin 
= lactitol 
Table 4. Comparison of disaccharides and rifaximin for hepatic encephalopathy. 
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study in order to compare the course of HE in patients treated with neomycin plus 
magnesium sulfate or with lactulose. The treatment groups were similar in terms of clinical 
characteristics, fatalities, recovery rate from grade 1 encephalopathy, and disappearance rate 
of neuropsychiatric signs. Transitions from severe to grade 1 or 0 encephalopathy showed a 
0.17 (NS) difference in favor of neomycin. Early therapy and evidence of precipitating 
factors showed a favorable prognostic significance. Ascites, hyperbilirubinemia, poor 
nutritional state, and hypoprothrombinemia showed bad prognostic significance. 
A combination of disaccharides and antibiotics is generally used in difficult to treat patients 
with HE, but clinical data is limited. In a retrospective chart review of 213 cases, Mantry and 
colleagues showed that the number of hospitalizations and the duration of hospital stays 
were shortened for patients receiving combination therapy compared with those receiving 
lactulose monotherapy. Additional studies to further investigate the potential therapeutic 
benefit of combination therapy will be needed.(77,78)  
9. Disaccharides versus other therapy for hepatic encephalopathy  
Mittal et al(79) compared lactulose, probiotics, and L-ornithine L-aspartate (LOLA) in 
treatment of MHE and effect on health related quality of life by Sickness Impact Profile 
questionnaire. MHE improved significantly in all three treatment groups. Lactulose, 
probiotics, and LOLA significantly improve MHE and health related quality of life in 
patients with chronic liver disease. Similar results were found in other studies (80,81) 
Table-5 
Trial 
Study 
design 
No of 
patients 
Type of 
patient 
Treatment assessment Efficacy 
Loguercio et al 
1987(82) 
Parallel 40 CHE Lactobacillus 
SF68 / 
lactulose 
PSE 
parameters, 
adverse 
events 
SF68=lactulose 
Loguercio et al 
1995(83) 
Parallel 40 CHE Lactobacillus 
SF68 / 
lactulose 
PSE 
parameters, 
adverse 
events 
SF68=lactulose 
Sushma et al 
1992(84) 
Parallel 74 AHE Sodium 
benzoate / 
lactulose 
Mortality, 
PSE 
parameters 
Sodium 
benzoate=lactulose 
Fiaccadori 
1980(86) 
Parallel 23 AHE + 
CHE 
BCAA/BCA
A 
+ lactulose / 
lactulose 
Clinical 
grading 
BCAA+lactulose> 
BCAA/lactulose 
Rossi- 
Fanelli 1982(87) 
Parallel 40 AHE BCAA / 
lactulose 
Clinical 
grading 
BCAA=Lactulose 
Table 5. Disaccharides versus other therapy for hepatic encephalopathy. 
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Loguercio et al. (82) in 40 patients with cirrhosis on a dietary protein regimen of 1 g/kg 
determined the effect on chronic hepatic encephalopathy of long-term administration of 
Enterococcus faecium (SF68) versus lactulose. The patients received one of the two 
treatments for three periods of 4 weeks, each separated by drug-free 2-week intervals. The 
efficacy of treatment was assessed by arterial blood ammonia concentration, mental status, 
number connection (Reitan's part A) test and flash-evoked visual potentials. At the end of 
the third period the reduction in both blood ammonia concentrations and Reitan's test times 
was more enhanced in patients on SF68 than in patients on lactulose. In conclusion, SF68 is 
at least as useful as lactulose for the chronic treatment of chronic hepatic encephalopathy; it 
has no adverse effects, and treatment can be interrupted for 2 weeks without losing the 
beneficial effects. 
Sushma et al(84) conducted a prospective randomized double-blind study to evaluate the 
efficacy of sodium benzoate in the treatment of acute portal-systemic encephalopathy. 
Seventy-four consecutive patients with cirrhosis or surgical portasystemic anastomosis and 
hepatic encephalopathy of less than 7 days duration were randomized to receive lactulose 
(dose adjusted for 2 or 3 semiformed stools/day) or sodium benzoate (5 gm twice daily). 
Assessment of response included mental status, asterixis, arterial ammonia level, 
electroencephalogram and number-connection test. The incidence of side effects was similar 
in the two treatment groups. The cost of lactulose for one course of therapy was 30 times 
that of sodium benzoate. They concluded that sodium benzoate is a safe and effective 
alternative to lactulose in the treatment of acute portasystemic encephalopathy. However in 
a study by Efrati et al (85) Blood ammonia increased after the glutamine load both before 
(from 66 ± 12 mg/dl to 123 ± 34 mg/dl and 179± 53 mg/dl after 30 and 60 min, respectively; 
p< 0.0004) and after benzoate treatment (from 102±27 mg/dl to 185 ±49 mg/dl and 250±39 
mg/dl after 30 and 60 min, respectively; p< 0.00001).The Number Connection test and the 
Posner’s test were not altered by benzoate treatment and this study suggests a note of 
caution in the use of sodium benzoate in cirrhotic patients. 
Rossi-Fanelli F et al(87) conducted a controlled study in two groups of 20 cirrhotic patients 
with deep coma in order to compare the efficacy of intravenous branched-chain amino acid 
solutions in 20% glucose (group A) vs. lactulose plus glucose in isocaloric amount (group B). 
Complete mental recovery was obtained in 70% of patients in group A and in 47% in group 
B. They concluded that , branched-chain amino acids are at least as effective as lactulose in 
deep hepatic coma. However, in a meta-analysis of eleven randomised trials (556 patients) 
assessing BCAA versus carbohydrates, neomycin/lactulose, or isonitrogenous control. 
There was no significant evidence of an effect of BCAA on improvement of hepatic 
encephalopathy in trials with adequate generation of the allocation sequence (RR 1.01, 95% 
CI 0.84 to 1.23, three trials), adequate allocation concealment (RR 1.09, 95% CI 0.89 to 1.33, 
five trials), or adequate double-blinding (RR 1.20, 95% CI 0.83 to 1.73, three trials). So it was 
concluded that BCAA had no significant beneficial effect on patients with hepatic 
encephalopathy (88). 
10. Disaccharides for primary prophylaxis of hepatic encephalopathy  
Certain patients are at risk of development of HE like patients with minimal hepatic 
encephalopathy and those with advanced liver disease (89-91). Variceal bleed is an 
important precipitating factor for HE in patients with cirrhosis. In a randomized trial, (92) 
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we enrolled seventy patients with acute variceal bleed into group-1(lactulose, n = 35) and 
group-2 (no lactulose, n = 35). Nineteen (27%) patients developed HE, 5 patients (14%) in the 
lactulose and 14 patients (40%) in no lactulose, p = 0.03. On multivariate analysis, only 
baseline arterial ammonia, blood requirement during hospital stay and no lactulose therapy 
were predictors of development of HE. Hence, lactulose was effective in preventing HE in 
these patients. We therefore, recommend lactulose (30-60ml/day) so that patients pass two 
to three semi formed stools in a day in these subsets of patients.  
Recently our group has shown in a randomized trial (93) involving 120(48%) patients, 
receiving either lactulose (n=60) or no lactulose (n=60). Twenty (19%) of 105 patients 
followed for 12 mo developed an episode of overt HE. Six (11%) of 55 in the lactulose group 
and 14(28%) of 50 in the no lactulose group (p=0.02) developed HE. Ten (20%) of 50 patients 
no lactulose group and 5(9%) of 55 patients lactulose group died, p=0.16. On multivariate 
analysis, Child’s score and presence of MHE at baseline was significantly associated with 
development of HE. Lactulose is effective in the primary prevention of HE.  
11. Disaccharides for secondary prophylaxis of hepatic encephalopathy  
Hepatic encephalopathy may be a cyclic condition in which patients develop overt HE, 
receive treatment, enter remission, and relapse. The emergence of HE after transjugular 
intrahepatic portosystemic shunt (TIPS) is of major concern for patients undergoing this 
procedure for refractory ascites or for prevention of variceal rebleeding. This clinical 
complication tends to occur within the first few days post-procedure. 
Although the majority of post-TIPS HE episodes are mild and responsive to 
pharmacological therapy, there are some cases where intractable HE develops and 
hospitalization is required. There are limited data on the use of drug therapy for the 
prophylaxis of HE after a TIPS procedure or in patients who have recovered from an 
episode of HE who may benefit from pharmacological prophylaxis to prevent future 
recurrences. Until recently, there has not been any conclusive evidence to support routine 
use of pharmacological prophylaxis for this purpose. Riggio and colleagues (94) conducted 
the first randomized controlled trial utilizing lactitol or rifaximin as pharmacological 
prophylaxis of post-shunt HE. Seventy-five consecutive patients with cirrhosis undergoing a 
TIPS procedure were randomized to receive lactitol 60mL/day, rifaximin 1200 mg/day or 
no treatment. Patients in the rifaximin or no-treatment groups were allowed administration 
of a sorbitol enema (120mL) in cases of minimal bowel movement (<1 bowel 
movement/day). Treatments were continued for 1 month post-TIPS or until the occurrence 
of an episode of HE. There was no significant difference in rate of HE occurrence among the 
three patient groups (p = 0.97).  
Two recent clinical trials have been conducted to evaluate the efficacy of lactulose or 
rifaximin used concomitantly with lactulose, as secondary prophylaxis of overt HE 
compared with placebo(95,96). Sharma and colleagues(95) conducted a single-centre, open-
label, randomized controlled trial in 125 cirrhotic patients who had recovered from at least 
one previous episode of HE. Patients were randomized to receive either lactulose 30–
60mL/day or placebo. Development of overt HE was the primary study endpoint. At the 
end of a median follow-up time of 14 months, significantly more patients in the placebo 
group (30 of 64 patients [46.8%]) than in the lactulose group (12 of 61 patients [19.6%]) 
developed HE (p = 0.001).  
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In a recent multicenter double blind randomized clinical trial to assess the secondary 
prevention of HE Bass and colleagues(96), enrolled 299 cirrhotic patients with a history of at 
least two episodes of overt HE to receive either rifaximin (550 mg twice daily; n = 140) or 
placebo (n = 159) for a period of 6 months. All enrolled patients had Model for End-Stage Liver 
Disease (MELD) scores of <25. More than 90% of patients in both groups were also maintained 
on concomitant lactulose therapy. A significantly lower percentage of patients in the rifaximin 
group (22.1%) experienced a breakthrough HE episode during the study period than in the 
placebo group (45.9%), with a hazard ratio (HR) of 0.42 (95% CI 0.28, 0.64;p < 0.001). In 
addition, there was a significantly reduced risk of hospitalization due to hepatic 
encephalopathy in the rifaximin patient group when compared with placebo; 19 patients in the 
rifaximin group (13.6%) versus 36 patients in the placebo group (22.6%),(p = 0.01). No 
significant difference in the incidence of adverse events was found between the two groups. In 
a similar study by Sanyal et al(97) patients with cirrhosis in remission from HE (Conn score = 
0 or 1) and a documented history of recurrent HE episodes (≥2 within 6 months of screening) 
were randomised to rifaximin 550 mg twice daily (N = 101) or placebo (N = 118) for 6 
months. Concomitant lactulose was permitted during the study. The Chronic Liver Disease 
Questionnaire (CLDQ) was administered every 4 weeks, and time for occurrence of HE 
breakthrough was recorded. The time-weighted averages of the overall CLDQ score and each 
domain score were significantly higher in the rifaximin group vs. placebo (P-values ranged 
from 0.0087 to 0.0436); and were significantly lower in patients who experienced HE 
breakthrough compared to those who remained in remission (P-values were <0.0001)(Table-6). 
Hence lactulose and rifaximin for the secondary prophylaxis of HE is recommended. 
 
Trial Study design 
No of 
patients 
Duration of 
treatment 
assessment Efficacy 
Sharma BC 
et al 
(2009)(69) 
Lactulose (open-
label) 
140 14months Psychometry 
and CFF 
Lactulose> 
no treatment 
Bass et al 
(2010)(70) 
Rifxaximin+lactulose
(randomized, 
double-blind, 
placebo-controlled) 
299 6 months HE clinical  Rifaximin 
>placebo 
Table 6. Disaccharides for secondary prophylaxis of hepatic encephalopathy. 
12. Conclusion 
Current pharmacotherapy for the management of HE is fairly limited, mainly because of the 
complex and relatively limited understanding of the pathophysiology of the disorder. 
Although the evidence of ammonia is robust, in everyday clinical practice a consistent 
correlation between the concentration of ammonia in the blood and the manifest symptoms 
of HE is not observed. More recently the synergistic role of inflammation and infection in 
modulating the cerebral effects of ammonia has been shown to be important. The most 
commonly utilized pharmacological agents include the non-absorbable disaccharides 
lactulose and lactitol, and the antimicrobial agent rifaximin. Lactulose and lactitol, the 
synthetic compounds of lactose, are poorly absorbed from the small intestine, and both are 
almost exclusively metabolized by the bacterial flora of the colon. These disaccharides 
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shorten the small bowel transit time mechanically and lower the pH of the bowel, both by 
their osmotic effects and by the acidic pH of their metabolites hence diminish the absorption 
of ammonia. Lactulose and lactitol are the classical therapy of choice for the treatment of 
hepatic encephalopathy. Recent literature has questioned the clinical efficacy of 
disaccharides in improving morbidity and mortality in patients with HE and, although 
antimicrobial agents such rifaximin have had an established role in the treatment of low 
grade (West Haven grade 1 and 2) encephalopathy, its use in high grade HE (grade 3 and 4) 
needs more data. Till we have more definitive agents non-absorbable disaccharides lactulose 
still continues to be the first line therapy for the prevention, treatment and secondary 
prophylaxis of hepatic encephalopathy.  
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